US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

39.18

+0.56031.45%

Post-market: 39.260.0846+0.22%16:17 EDT

Volume:48.07K

Turnover:1.88M

Market Cap:357.28M

PE:- -

High:39.27

Open:38.72

Low:38.72

Close:38.62

52wk High:39.80

52wk Low:30.66

Shares:9.12M

Float Shares:9.12M

Volume Ratio:1.47

T/O Rate:0.53%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: BeyondSpring Reports 2025 Year-End Financial Results

Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)

Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial

Press Release: Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update

NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer

CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

New Variable in Pan-KRAS Space: Valuation Gap Behind JAB-23E73's 38.5% ORR in Pancreatic Cancer

Press Release: Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/ORR/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":39.1754,"timestamp":1788465600000,"preClose":38.6151,"halted":0,"volume":48071,"hourTrading":{"tag":"盘后","latestPrice":39.26,"preClose":39.1754,"latestTime":"16:17 EDT","volume":11,"amount":431.10782,"timestamp":1788466626280,"change":0.0846,"changeRate":0.00216,"amplitude":0.00216},"delay":0,"changeRate":0.014509867901416937,"floatShares":9120000,"shares":9120000,"eps":0,"marketStatus":"Post-Mkt","change":0.5603,"latestTime":"09-03 16:39:53 EDT","open":38.72,"high":39.27,"low":38.72,"amount":1881042,"amplitude":0.014243,"askPrice":42.87,"askSize":100,"bidPrice":39.26,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788480000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":38.6151,"sharesOutstanding":12900000,"nav":38.79,"aum":353764800,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":39.26,"preClose":39.1754,"latestTime":"16:17 EDT","volume":11,"amount":431.10782,"timestamp":1788466626280,"change":0.0846,"changeRate":0.00216,"amplitude":0.00216},"volumeRatio":1.466053,"impliedVol":0.1703,"impliedVolPercentile":0.6084},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9120000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.466053,"shares":9120000,"dividePrice":0,"high":39.27,"amplitude":0.014243,"preClose":38.6151,"low":38.72,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":39.1754,"committee":0.666667,"eps":0,"divideRate":0,"volume":48071,"delay":0,"ttmEps":0,"open":38.72,"prevYearClose":34.16,"prevWeekClose":38.9187,"prevMonthClose":38.77,"prevQuarterClose":36.32,"fiveDayClose":38.8951,"twentyDayClose":39.52,"sixtyDayClose":35.545},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622107545","title":"Press Release: BeyondSpring Reports 2025 Year-End Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622107545","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622107545?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:30","pubTimestamp":1774441800,"startTime":"0","endTime":"0","summary":"-- Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel. standard of care docetaxel in EGFR wild-type NSCLC patients whose tumors. progressed after first line therapy -- DUBLIN-3 study results published. discussions, BeyondSpring is advancing DUBLIN-4, a confirmatory global. Phase 3 study in a biomarker-selected EGFR wild-type NSCLC patient. sensitivity to checkpoint inhibitors -- a significant unmet need. Cell Press journal Med 2025 and presented at SITC 2025. \"2025 was a year of important clinical and operational progress for BeyondSpring and SEED Therapeutics,\" said Dr. Lan Huang, Co-Founder, Chairman and Chief Executive Officer of BeyondSpring. \"We advanced our Phase 3 Plinabulin program, generated meaningful clinical data, and strengthened our strategic and financial position.\". \"BeyondSpring made meaningful progress advancing Plinabulin in Phase 3 NSCLC, while SEED Therapeutics reached a critical milestone -- initiating its first clinical trial following IND cle","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYSI","BK4097","OS","BK4225","BK4211","BK4195","BK4139","HR","ORR","BK4203","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621809037","title":"Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621809037","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621809037?lang=en_us&edition=fundamental","pubTime":"2026-03-24 11:32","pubTimestamp":1774323120,"startTime":"0","endTime":"0","summary":"Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung cancer. SINGAPORE, March 24, 2026 /PRNewswire/ -- Prestige Biopharma today announced positivetopline results from its Phase 3 SAMSON-II study evaluating HD204, a proposed biosimilar to Avastin  in adult patients with advanced non-squamous non-small cell lung cancer .SAMSON-II is a randomized, double blind, parallel group, multicenter Phase 3 study conducted in 625 patients across 91 centers in 15 countries. Patients were randomized in a 1:1 ratio to receive HD204 or Avastin in combination with standard chemotherapy.\"These results illustrate the increasing precision with which biosimilarity can be established through advanced analytical and clinical PK studies,\" said Dr. Lisa Park, Chief Executive Officer of Prestige Biopharma. \"Our experience with HD204 supports the view that well-designed development programs can reliably anticipate cl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prestige-biopharma-announces-positive-topline-results-from-comparative-samson-ii-study-for-hd204-a-potential-biosimilar-to-avastin-bevacizumab-302722770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4181","BK7095","ORR","PFS","PK","ORR.AU","PBH","OS","BK4211","BK4195","BK4218","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621706487","title":"Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706487","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706487?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:45","pubTimestamp":1774269900,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS Formal centralized and independent analysis of the clinical response data from the ACCENT trial has been undertaken and updated analysis provided to the CompanyThe data confirm that five (5","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260403/0/en/Amplia-Therapeutics-Reports-Four-Additional-Complete-Responses-and-Improved-Overall-Survival-Data-in-Accent-Pancreatic-Cancer-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","INNMF","OS","PFS","BK4195","BK4539","BK4161","CR","BK4139","LENZ","BK4007","BK4097","PR","BK4211","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621777299","title":"Press Release: Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2621777299","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621777299?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:00","pubTimestamp":1774263600,"startTime":"0","endTime":"0","summary":"Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track for mid-year 2026; to include patients treated with modified weight-based dosing and patients treated with total body weight dosing. Updated data from MICVO Phase 1/2 dose escalation study in combination with KEYTRUDA in 1L/2L+ R/M HNSCC on track for the second half of 2026. Announced appointment of Thomas Civik as Interim Chief Executive Officer. Expected cash runway into the fourth quarter of 2026. BOSTON, March 23, 2026  -- Pyxis Oncology, Inc. , a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today provided a business update, and reported financial results for the year and quarter ended December 31, 2025.-- Pyxis Oncology announced positive preliminary data for micvotabart. -- Monotherapy: 46% confirmed objective response rate  and 92%. disease control rate  observed with MICVO as monotherapy in. 2L+ R/M HNSCC . MICVO as monotherapy was. generally well tolera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","L","BK4022","BK4107","ORR","LU2487616109.SGD","BK4139","LU0053666078.USD","BK4588","R","LU0210528500.USD","BK4232","PYXS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620779332","title":"Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620779332","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620779332?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:21","pubTimestamp":1773962460,"startTime":"0","endTime":"0","summary":"Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became eligibl","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3259513/0/en/Cellectis-Reports-Full-Year-2025-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","IE0031619046.USD","OS","BK4097","BK4006","CLLS","CRS","IE00B7SZL793.SGD","LU0963586101.USD","BK4139","LU2065731478.USD","LU2463526074.USD","IE00B19Z4B17.USD","BK4109","ORR","IE00B66KJ199.SGD","BK4187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619450780","title":"NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450780","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450780?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658800,"startTime":"0","endTime":"0","summary":"FDA confirmed givastomig’s potential eligibility for an accelerated approval pathwayNovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective respo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256129/0/en/NovaBridge-Announces-Productive-FDA-Type-B-Meeting-on-Potential-Accelerated-Approval-Pathway-for-Givastomig-in-Gastric-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619269450","title":"CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2619269450","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619269450?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658800,"startTime":"0","endTime":"0","summary":"- Confirmed response rates in expansion cohorts of32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Gr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256138/37704/en/CytomX-s-Varsetatug-Masetecan-EpCAM-PROBODY-ADC-Continues-to-Demonstrate-Positive-Data-Supporting-Potential-as-a-New-Treatment-Option-in-Late-Line-Colorectal-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","TRAE","BK4231","BK4195","BK4211","ADC","CRC","LU0456854461.SGD","LU0266512127.USD","BK4080","BK4213","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618412132","title":"SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009","url":"https://stock-news.laohu8.com/highlight/detail?id=2618412132","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618412132?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:35","pubTimestamp":1773318900,"startTime":"0","endTime":"0","summary":"- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS’ Predictive Biomarker and AI Assisted Precision Medicine Models to be Utili","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/12/3254670/0/en/SELLAS-Life-Sciences-Announces-Enrollment-of-First-Patient-in-Newly-Diagnosed-First-Line-AML-Trial-of-SLS009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170989075","title":"New Variable in Pan-KRAS Space: Valuation Gap Behind JAB-23E73's 38.5% ORR in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1170989075","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170989075?lang=en_us&edition=fundamental","pubTime":"2026-03-11 09:27","pubTimestamp":1773192420,"startTime":"0","endTime":"0","summary":"Recent disclosures in the Pan-KRAS field have revealed a set of data worthy of close examination. JACOBIO-B (01167) announced Phase I study results for JAB-23E73 in pancreatic cancer patients. The...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01167","ORR","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618396674","title":"Press Release: Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618396674","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618396674?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:02","pubTimestamp":1773086520,"startTime":"0","endTime":"0","summary":"- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment -. \"The pace of progress at Alpha Tau today is unlike anything we've ever seen before,\" said Alpha Tau Chief Executive Officer Uzi Sofer. \"With a slew of meaningful announcements in the past few months, culminating most recently with our receipt of marketing approval in Japan, our first outside of Israel, and with multiple meaningful milestones targeted for the coming months, we remain laser focused on execution. Clinical trial progress remains our highest priority, with an astounding five clinical trials approved in parallel in the U.S. At the same time, we continue to build out our manufacturing capabilities in New Hampshire as well as our pre-commercial preparations, while entertaining multiple tracks of strategic dialogue with partners who show increas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ORR","IDE","BK4022","BK4232","R","DRTS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":7,"totalSize":130,"code":"91000000","status":"200"}]}}